High Growth Tech Stocks To Watch In The US September 2026

The United States market has remained flat over the past week but has seen a 12% increase over the last year, with earnings anticipated to grow by 17% annually in the coming years. In this context, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability, aligning well with expected earnings growth and overall market trends.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Fabrinet	21.15%	21.40%	★★★★★★
Coherent	30.45%	43.85%	★★★★★★
Ciena	21.40%	35.22%	★★★★★★
TG Therapeutics	21.54%	21.27%	★★★★★★
Lumentum Holdings	42.18%	92.37%	★★★★★★
Shopify	20.16%	21.03%	★★★★★★
Madrigal Pharmaceuticals	27.97%	63.67%	★★★★★★
Travere Therapeutics	24.30%	53.11%	★★★★★★
Snowflake	21.07%	56.66%	★★★★★★
Precigen	34.82%	55.42%	★★★★★★

Click here to see the full list of 24 stocks from our US High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Flex (FLEX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Flex Ltd. offers technology innovation, supply chain, and manufacturing solutions across various industries including data center, communications, enterprise, consumer, automotive, healthcare, industrial, and power sectors globally with a market cap of approximately $40.08 billion.

Operations: Flex Ltd. generates revenue through three main segments: Cloud and Power Infrastructure ($7.19 billion), Integrated Technology Solutions ($11.61 billion), and Regulated Manufacturing Solutions ($10.47 billion).

Flex's strategic moves, including the appointment of Amy B. Schwetz as CFO and the expansion of its board, underscore its commitment to robust financial and operational leadership. The company's focus on advanced manufacturing capabilities is evident in its partnership to scale up production of the Cerebras CS-3 AI system, a key growth driver within the tech sector. This initiative not only enhances Flex's manufacturing prowess but also aligns with industry trends towards sophisticated AI solutions. Financially, Flex has shown impressive performance with a significant revision in earnings guidance for FY 2027, projecting sales between $33.7 billion and $35.2 billion—a 23% increase at the midpoint from previous forecasts. Such financial health is bolstered by strong R&D investments that support sustained innovation and competitive advantage in high-growth tech markets.

• Take a closer look at Flex's potential here in our health report.

• Learn about Flex's historical performance.

Ionis Pharmaceuticals (IONS)

Simply Wall St Growth Rating: ★★★★★★

Overview: Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on providing RNA-targeted medicines in the United States, with a market capitalization of $7.39 billion.

Operations: Ionis Pharmaceuticals generates revenue primarily through its Ionis Operations segment, which reported $874.09 million. The company focuses on developing RNA-targeted medicines in the U.S., leveraging its biotechnology expertise to drive growth within this specialized market.

Ionis Pharmaceuticals is navigating a transformative phase with significant R&D investments, which totaled 23% of its revenue last year, underscoring its commitment to innovation despite recent setbacks in clinical trials. The company's focus on RNA-targeted therapies has yielded FDA approval for ZANVASTRO for Alexander disease, marking a milestone as the first treatment addressing this rare neurological disorder's underlying mechanism. Although the Lp(a)HORIZON study did not meet its primary endpoint, Ionis continues to advance its pipeline with promising therapies like TRYNGOLZA for severe hypertriglyceridemia, demonstrating resilience and adaptability in high-stakes biotech environments.

• Click here and access our complete health analysis report to understand the dynamics of Ionis Pharmaceuticals.

• Understand Ionis Pharmaceuticals' track record by examining our Past report.

Seagate Technology Holdings (STX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Seagate Technology Holdings plc is a global company that specializes in providing data storage solutions across various regions, including Singapore, the United States, and the Netherlands, with a market capitalization of approximately $195.28 billion.

Operations: Seagate focuses on the manufacture and distribution of storage solutions, generating $12.20 billion in revenue.

Seagate Technology Holdings has demonstrated robust financial performance with a significant uptick in annual revenue and earnings, growing by 22.5% and 114.6% respectively. This growth trajectory is supported by strategic R&D investments, which are essential for innovation in the competitive tech landscape. Recently, the company showcased its forward-looking initiatives at several high-profile conferences, underlining its commitment to advancing technology in storage solutions. Additionally, Seagate's recent share repurchase of $106.72 million underscores its confidence in ongoing business strength and commitment to shareholder value. These factors collectively highlight Seagate's potential to maintain its momentum amidst dynamic market conditions.

• Get an in-depth perspective on Seagate Technology Holdings' performance by reading our health report here.

• Evaluate Seagate Technology Holdings' historical performance by accessing our past performance report.

Turning Ideas Into Actions

• Click this link to deep-dive into the 24 companies within our US High Growth Tech and AI Stocks screener.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com